# Arvinas Inc. (ARVN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.39, market value $606 million.

## Valuation
- **P/E (trailing): 36.1×**. Arvinas Inc. trades at 36.1× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 1.1×**. The shares trade at 1.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -34.5%** (5-yr avg -13.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 2.8%**. The inverse of the P/E: 2.8% of the price is earned each year.

## Profitability
- **Operating margin: -5.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -30.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -18.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -4.9%**. Return on all capital, debt included, is -4.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.3%**. Each dollar of assets produces 1.3% of profit.

## Growth
- **Revenue growth (1 yr): -0.3%** (3-yr 26.0%/yr, 5-yr 64.5%/yr). Revenue fell 0.3% over the last year, against 64.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 58.8%**. Earnings per share rose 58.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 9.4×**. It would take 9.4 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 1.95**. A Z-score of 1.95 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Arvinas Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (14 analysts). 14 analysts cover Arvinas Inc.; the consensus is buy, with an average price target of $13.93 (+48% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 23.4%** (YTD -20.8%, 3-mo 26.5%). The shares are up 23.4% over twelve months including dividends.
- **From 52-week high: -35.3%** (34.7% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 1.04** (volatility 54%). Beta of 1.04 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARVN · Page: https://foliofundamentals.com/stocks/arvn

Not investment advice.